Understanding the biology of reactive oxygen species and their link to cancer: NADPH oxidases as novel pharmacological targets

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 8, 2014, Pages 533-542

  Harrison, Ian P ^a   Selemidis, Stavros ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Angiogenesis; Cancer; Cell proliferation; NADPH oxidase; Nox; Oxidative stress; Reactive oxygen species; Superoxide

Indexed keywords

ANTIOXIDANT; OXIDOREDUCTASE INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CARDIOMYOPATHY; DRUG TARGETING; HUMAN; HYPOGLYCEMIA; IMMUNOCOMPETENT CELL; INTRACELLULAR SIGNALING; NEOPLASM; PHYSIOLOGICAL PROCESS; PROTEIN TARGETING; TUMOR CELL; ANIMAL; ENZYMOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANIMALS; CARCINOGENESIS; HUMANS; NADPH OXIDASE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REACTIVE OXYGEN SPECIES;

EID: 84906249425     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12238     Document Type: Article

References (155)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010; 127: 2893-917.
2. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: Priorities for prevention. Carcinogenesis 2010; 31: 100-10.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-74.
4. Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J. Clin. 1972; 22: 226-9.
5. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 1990; 82: 4-6.
6. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
7. Bono F, De Smet F, Herbert C et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 2013; 23: 477-88.
8. Schmidt T, Carmeliet P. Angiogenesis. A target in solid tumors, also in leukemia? Hematology Am. Soc. Hematol. Educ. Program 2011; 2011: 1-8.
9. Brait VH, Jackman KA, Walduck AK et al. Mechanisms contributing to cerebral infarct size after stroke: Gender, reperfusion, T lymphocytes, and Nox2-derived superoxide. J. Cereb. Blood Flow Metab. 2010; 30: 1306-17.
10. Judkins CP, Diep H, Broughton BRS et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am. J. Physiol. Heart Circ. Physiol. 2010; 298: H24-32.
11. Yatmaz S, Seow HJ, Gualano RC et al. Glutathione peroxidase-1 reduces influenza A virus-induced lung inflammation. Am. J. Respir. Cell Mol. Biol. 2013; 48: 17-26.
12. Vlahos R, Stambas J, Bozinovski S, Broughton BRS, Drummond GR, Selemidis S. Inhibition of Nox2 oxidase activity ameliorates influenza a virus-induced lung inflammation. PLoS Pathog. 2011; 7: 2.
13. Vlahos R, Stambas J, Selemidis S. Suppressing production of reactive oxygen species (ROS) for influenza A virus therapy. Trends Pharmacol. Sci. 2012; 33: 3-8.
14. Folkman J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann. Surg. 1972; 175: 409-16.
15. Sabrkhany S, Griffioen AW, Oude Egbrink MGA. The role of blood platelets in tumor angiogenesis. Biochim. Biophys. Acta 2011; 1815: 189-96.
16. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
17. Layman H, Rahnemai-Azar AA, Pham SM, Tsechpenakis G, Andreopoulos FM. Synergistic angiogenic effect of codelivering fibroblast growth factor 2 and granulocyte-colony stimulating factor from fibrin scaffolds and bone marrow transplantation in critical limb ischemia. Tissue Eng. Part A 2011; 17: 243-54.
18. Garrido-Urbani S, Jemelin S, Deffert C et al. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism. PLoS One 2011; 6: 2.
19. Laise P, Di Patti F, Fanelli D, Masselli M, Arcangeli A. Deterministic and stochastic aspects of VEGF-A production and the cooperative behavior of tumoral cell colony. J. Theor. Biol. 2011; 272: 55-63.
20. Folkman J. Angiogenesis. Annu. Rev. Med. 2006; 57: 1-18.
21. Kerbel RS. Tumor angiogenesis. N. Engl. J. Med. 2008; 358: 2039-49.
22. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 2003; 9: 653-60.
23. Napoli C, Giordano A, Casamassimi A, Pentimalli F, Ignarro LJ, De Nigris F. Directed in vivo angiogenesis assay and the study of systemic neoangiogenesis in cancer. Int. J. Cancer 2011; 128: 1505-8.
24. Di Domenico M, Ricciardi C, Fusco A, Pierantoni GM. Anti VEGF therapy in breast and lung mouse models of cancers. J. Biomed. Biotechnol. 2011; 2011: 947928.
25. Ebos JML, Lee CR, Bogdanovic E et al. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res. 2008; 68: 521-9.
26. Bir SC, Shen X, Kavanagh TJ, Kevil CG, Pattillo CB. Control of angiogenesis dictated by picomolar superoxide levels. Free Radic. Biol. Med. 2013; 63: 135-42.
27. Sanci M, Dikis C, Inan S, Turkoz E, Dicle N, Ispahi C. Immunolocalization of VEGF, VEGF receptors, EGF-R and Ki-67 in leiomyoma, cellular leiomyoma and leiomyosarcoma. Acta Histochem. 2011; 113: 317-25.
28. Sun T, Cao H, Xu L, Zhu B, Gu Q, Xu X. Insulin-like growth factor binding protein-related protein 1 mediates VEGF-induced proliferation, migration and tube formation of retinal endothelial cells. Curr. Eye Res. 2011; 36: 341-9.
29. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted 86Y-CHX-A''-DTPA-bevacizumab. Int. J. Cancer 2011; 128: 920-6.
30. Welti JC, Gourlaouen M, Powles T et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2011; 30: 1183-93.
31. Berrios RL, Arbiser JL. Novel antiangiogenic agents in dermatology. Arch. Biochem. Biophys. 2011; 508: 222-6.
32. Watt SM, Athanassopoulos A, Harris AL, Tsaknakis G. Human endothelial stem/progenitor cells, angiogenic factors and vascular repair. J. R. Soc. Interface 2010; 7 (Suppl. 6): S731-51.
33. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat. Rev. Cancer 2003; 3: 276-85.
34. Das S, Singh G, Baker AB. Overcoming disease-induced growth factor resistance in therapeutic angiogenesis using recombinant co-receptors delivered by a liposomal system. Biomaterials 2014; 35: 196-205.
35. Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic. Res. 2010; 44: 479-96.
36. Ammar RF, Gutterman DD, Brooks LA, Dellsperger KC. Free radicals mediate endothelial dysfunction of coronary arterioles in diabetes. Cardiovasc. Res. 1970; 4: 595-601.
37. Pendyala S, Natarajan V. Redox regulation of Nox proteins. Respir. Physiol. Neurobiol. 2010; 174: 265-71.
38. Zhao MM, Xu MJ, Cai Y et al. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney Int. 2011; 79: 1071-9.
39. Richter C, Gogvadze V, Laffranchi R et al. Oxidants in mitochondria: From physiology to diseases. Biochim. Biophys. Acta 1995; 1271: 67-74.
40. Szumiel I. Autophagy, reactive oxygen species and the fate of mammalian cells. Free Radic. Res. 2011; 45: 253-65.
41. Rajashekhar G, Kamocka M, Marin A et al. Pro-inflammatory angiogenesis is mediated by p38 MAP kinase. J. Cell. Physiol. 2011; 226: 800-8.
42. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 2004; 7: 97-110.
43. Indo HP, Davidson M, Yen H-C et al. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion 2007; 7: 106-18.
44. Schaeffer AJ. Editorial: Emerging concepts in the management of prostatitis/chronic pelvic pain syndrome. J. Urol. 2003; 169: 597-8.
45. Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem. Soc. Trans. 2003; 31: 1441-4.
46. Kang D, Hamasaki N. Mitochondrial oxidative stress and mitochondrial DNA. Clin. Chem. Lab. Med. 2003; 41: 1281-8.
47. Toyokuni S. Persistent oxidative stress in cancer. FEBS Lett. 1995; 358: 1-3.
48. Clemens MR. Free radicals in chemical carcinogenesis. Klin. Wochenschr. 1991; 69: 1123-34.
49. Ushio-Fukai M. VEGF signaling through NADPH oxidase-derived ROS. Antioxid. Redox Signal. 2007; 9: 731-9.
50. Chen JX, Chen Y, DeBusk L, Lin W, Lin PC. Dual functional roles of Tie-2/angiopoietin in TNF-α-mediated angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 2004; 287: H187-95.
51. Chen JX, Zeng H, Lawrence ML, Blackwell TS, Meyrick B. Angiopoietin-1-induced angiogenesis is modulated by endothelial NADPH oxidase. Am. J. Physiol. Heart Circ. Physiol. 2006; 291: H1563-72.
52. Keyer K, Gort AS, Imlay JA. Superoxide and the production of oxidative DNA damage. J. Bacteriol. 1995; 177: 6782-90.
53. Rister M, Baehner RL. The alteration of superoxide dismutase, catalase, glutathione peroxidase, and NAD(P)H cytochrome c reductase in guinea pig polymorphonuclear leukocytes and alveolar macrophages during hyperoxia. J. Clin. Invest. 1976; 58: 1174-84.
54. Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
55. Fraszczak J, Trad M, Janikashvili N et al. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. J. Immunol. 2010; 184: 1876-84.
56. Turan NN, Yildiz G, Gumusel B, Demiryurek AT. Ischemic and peroxynitrite preconditioning effects in chronic hypoxic rat lung. Exp. Lung Res. 2008; 34: 325-41.
57. Guzik TJ, West NEJ, Pillai R, Taggart DP, Channon KM. Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels. Hypertension 2002; 39: 1088-94.
58. White CR, Brock TA, Chang LY et al. Superoxide and peroxynitrite in atherosclerosis. Proc. Natl Acad. Sci. USA 1994; 91: 1044-8.
59. Fridovich I. Quantitative aspects of the production of superoxide anion radical by milk xanthine oxidase. J. Biol. Chem. 1970; 245: 4053-7.
60. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 1969; 244: 6049-55.
61. Ohno Y, Gallin JI. Diffusion of extracellular hydrogen peroxide into intracellular compartments of human neutrophils: Studies utilizing the inactivation of myeloperoxidase by hydrogen peroxide and azide. J. Biol. Chem. 1985; 260: 8438-46.
62. Koppenol WH. The Haber-Weiss cycle: 70 years later. Redox Rep. 2001; 6: 229-34.
63. Tonks NK. Protein tyrosine phosphatases: From genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 2006; 7: 833-46.
64. Julien SG, Dubé N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 2011; 11: 35-49.
65. Alonso A, Sasin J, Bottini N et al. Protein tyrosine phosphatases in the human genome. Cell 2004; 117: 699-711.
66. Shields BJ, Wiede F, Gurzov EN et al. TCPTP regulates SFK, STAT3 signaling and is lost in triple-negative breast cancers. Mol. Cell. Biol. 2013; 33: 557-70.
67. Karisch R, Neel BG. Methods to monitor classical protein-tyrosine phosphatase oxidation. FEBS J. 2013; 280: 459-75.
68. Zhang ZY. Mechanistic studies on protein tyrosine phosphatases. Prog. Nucleic Acid Res. Mol. Biol. 2003; 73: 171-220.
69. Tanner JJ, Parsons ZD, Cummings AH, Zhou H, Gates KS. Redox regulation of protein tyrosine phosphatases: Structural and chemical aspects. Antioxid. Redox Signal. 2011; 15: 77-97.
70. Tonks NK. Redox redux: Revisiting PTPs and the control of cell signaling. Cell 2005; 121: 667-70.
71. Mantovani A, Sica A. Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr. Opin. Immunol. 2010; 22: 231-7.
72. Shi Y, Liu L, Zhang T et al. The involvement of Helicobacter pylori thioredoxin-1 in gastric carcinogenesis. J. Med. Microbiol. 2013; 62: 1226-34.
73. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60: 78-83.
74. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ. Prostatitis as a risk factor for prostate cancer. Epidemiology 2004; 15: 93-9.
75. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. The polarization of immune cells in the tumour environment by TGFβ2. Nat. Rev. Immunol. 2010; 10: 554-67.
76. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
77. Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-6.
78. Coso S, Harrison I, Harrison CB et al. NADPH oxidases as regulators of tumor angiogenesis: Current and emerging concepts. Antioxid. Redox Signal. 2012; 16: 1229-47.
79. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004; 10: 942-9.
80. Efimova O, Szankasi P, Kelley TW. Ncf1 (p47phox) is essential for direct regulatory T cell mediated suppression of CD4+ effector T cells. PLoS One 2011; 6: 1.
81. Lee K, Won HY, Bae MA, Hong JH, Hwang ES. Spontaneous and aging-dependent development of arthritis in NADPH oxidase 2 deficiency through altered differentiation of CD11b+ and Th/Treg cells. Proc. Natl Acad. Sci. USA 2011; 108: 9548-53.
82. Combs GF Jr, Gray WP. Chemopreventive agents: Selenium. Pharmacol. Ther. 1998; 79: 179-92.
83. Bostwick DG, Alexander EE, Singh R et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000; 89: 123-34.
84. Sikka SC. Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention: A mechanistic approach. Curr. Med. Chem. 2003; 10: 2679-92.
85. Cai T, Fassina G, Morini M et al. N-Acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab. Invest. 1999; 79: 1151-9.
86. Fontayne A, Dang PMC, Gougerot-Pocidalo MA, El Benna J. Phosphorylation of p47phox sites by PKCα, βII, δ and ζ: Effect on binding to p22phox and on NADPH oxidase activation. Biochemistry 2002; 41: 7743-50.
87. Wind S, Beuerlein K, Eucker T et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br. J. Pharmacol. 2010; 161: 885-98.
88. Sardas S. The role of antioxidants in cancer prevention and treatment. Indoor Built Environ. 2003; 12: 401-4.
89. Yoshihara D, Fujiwara N, Suzuki K. Antioxidants: Benefits and risks for long-term health. Maturitas 2010; 67: 103-7.
90. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl Acad. Sci. USA 2001; 98: 10350-5.
91. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev. 2007; 87: 245-313.
92. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 2011; 10: 453-71.
93. Selemidis S, Sobey CG, Wingler K, Schmidt HHHW, Drummond GR. NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. Pharmacol. Ther. 2008; 120: 254-91.
94. Streeter J, Thiel W, Brieger K, Miller FJ Jr. Opportunity Nox: The future of NADPH oxidases as therapeutic targets in cardiovascular disease. Cardiovasc. Ther. 2013; 31: 125-37.
95. Brandes RP, Weissmann N, Schroder K. Nox family NADPH oxidases in mechano-transduction: Mechanisms and consequences. Antioxid. Redox Signal. 2014; 20: 887-98.
96. Khan SA, Nanduri J, Yuan G et al. NADPH oxidase 2 mediates intermittent hypoxia-induced mitochondrial complex I inhibition: Relevance to blood pressure changes in rats. Antioxid. Redox Signal. 2011; 14: 533-42.
97. Ris-Stalpers C. Physiology and pathophysiology of the DUOXes. Antioxid. Redox Signal. 2006; 8: 1563-72.
98. Harrison CB, Selemidis S, Guida E, King PT, Sobey CG, Drummond GR. NOX2β: A novel splice variant of NOX2 that regulates NADPH oxidase activity in macrophages. PLoS One 2012; 7: 10.
99. Goyal P, Weissmann N, Rose F et al. Identification of novel Nox4 splice variants with impact on ROS levels in A549 cells. Biochem. Biophys. Res. Commun. 2005; 329: 32-9.
100. Anilkumar N, Jose GS, Sawyer I et al. A 28-kDa splice variant of NADPH oxidase-4 is nuclear-localized and involved in redox signaling in vascular cells. Arterioscler. Thromb. Vasc. Biol. 2013; 33: e104-12.
101. Al-Mehdi AB, Zhao G, Dodia C et al. Endothelial NADPH oxidase as the source of oxidants in lungs exposed to ischemia or high K+. Circ. Res. 1998; 83: 730-7.
102. De Keulenaer GW, Chappell DC, Ishizaka N, Nerem RM, Wayne Alexander R, Griendling KK. Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: Role of a superoxide-producing NADH oxidase. Circ. Res. 1998; 82: 1094-101.
103. Frey RS, Ushio-Fukai M, Malik AB. NADPH oxidase-dependent signaling in endothelial cells: Role in physiology and pathophysiology. Antioxid. Redox Signal. 2009; 11: 791-810.
104. Görlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ. Res. 2000; 87: 26-32.
105. Serrander L, Cartier L, Bedard K et al. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem. J. 2007; 406: 105-14.
106. Peshavariya H, Dusting GJ, Jiang F et al. NADPH oxidase isoform selective regulation of endothelial cell proliferation and survival. Naunyn Schmiedebergs Arch. Pharmacol. 2009; 380: 193-204.
107. Hanna IR, Hilenski LL, Dikalova A et al. Functional association of Nox1 with p22phox in vascular smooth muscle cells. Free Radic. Biol. Med. 2004; 37: 1542-9.
108. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: Recent advances in basic science. Lancet 2011; 378: 704-12.
109. Billottet C, Quemener C, Bikfalvi A. CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim. Biophys. Acta 2013; 1836: 287-95.
110. Wang H, Jiang Y, Shi D et al. Activation of Rap1 inhibits NADPH oxidase-dependent ROS generation in retinal pigment epithelium and reduces choroidal neovascularization. FASEB J. 2014; 28: 265-74.
111. Daugaard M, Nitsch R, Razaghi B et al. Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes. Nat. Commun. 2013; 4: 2180.
112. Meng D, Mei A, Liu J et al. NADPH oxidase 4 mediates insulin-stimulated HIF-1α and VEGF expression, and angiogenesis in vitro. PLoS One 2012; 7: 10.
113. Ushio-Fukai M, Tang Y, Fukai T et al. Novel role of gp91phox-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ. Res. 2002; 91: 1160-7.
114. Arbiser JL, Petros J, Klafter R et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc. Natl Acad. Sci. USA 2002; 99: 715-20.
115. Selemidis S, Seow HJ, Broughton BR et al. Nox1 oxidase suppresses influenza a virus-induced lung inflammation and oxidative stress. PLoS One 2013; 8: 8.
116. Johnson DK, Schillinger KJ, Kwait DM et al. Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols. Endothelium 2002; 9: 191-203.
117. Kinkade K, Streeter J, Miller FJ Jr. Inhibition of NADPH oxidase by apocynin attenuates progression of atherosclerosis. Int. J. Mol. Sci. 2013; 14: 17017-28.
118. Stolk J, Hiltermann T, Dijkman J, Verhoeven A. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am. J. Respir. Cell Mol. Biol. 1994; 11: 95-102.
119. O'Donnell VB, Smith GCM, Jones OTG. Involvement of phenyl radicals in lodonium compound inhibition of flavoenzymes. Mol. Pharmacol. 1994; 46: 778-85.
120. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O2- and systolic blood pressure in mice. Circ. Res. 2001; 89: 408-14.
121. Csányi G, Cifuentes-Pagano E, Al Ghouleh I et al. Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2. Free Radic. Biol. Med. 2011; 51: 1116-25.
122. Cifuentes-Pagano E, Meijles D, Pagano PJ. Sly as a Nox: The challenges, triumphs and pitfalls of selective NADPH oxidase inhibition. Antioxid. Redox Signal. 2014; doi: 10.1089/ars.2013.5620.
123. Perry BN, Govindarajan B, Bhandarkar SS et al. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J. Invest. Dermatol. 2006; 126: 2316-22.
124. Bhandarkar SS, Jaconi M, Fried LE et al. Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J. Clin. Invest. 2009; 119: 2359-65.
125. Schewe C, Schewe T, Wendel A. Strong inhibition of mammalian lipoxygenases by the antiinflammatory seleno-organic compound ebselen in the absence of glutathione. Biochem. Pharmacol. 1994; 48: 65-74.
126. Noguchi N, Gotoh N, Niki E. Effects of ebselen and probucol on oxidative modifications of lipid and protein of low density lipoprotein induced by free radicals. Biochim. Biophys. Acta 1994; 1213: 176-82.
127. Smith SME, Min J, Ganesh T et al. Ebselen and congeners inhibit NADPH oxidase 2-dependent superoxide generation by interrupting the binding of regulatory subunits. Chem. Biol. 2012; 19: 752-63.
128. Teng L, Fan LM, Meijles D, Li JM. Divergent effects of p47 phox phosphorylation at S303-4 or S379 on tumor necrosis factor-α signaling via TRAF4 and MAPK in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2012; 32: 1488-96.
129. Gianni D, Taulet N, Zhang H et al. A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. ACS Chem. Biol. 2010; 5: 981-93.
130. Kahles T, Brandes RP. NADPH oxidases as therapeutic targets in ischemic stroke. Cell. Mol. Life Sci. 2012; 69: 2345-63.
131. Altenhöfer S, Kleikers PWM, Radermacher KA et al. The NOX toolbox: Validating the role of NADPH oxidases in physiology and disease. Cell. Mol. Life Sci. 2012; 69: 2327-43.
132. Wingler K, Altenhoefer SA, Kleikers PWM, Radermacher KA, Kleinschnitz C, Schmidt HHHW. VAS2870 is a pan-NADPH oxidase inhibitor. Cell. Mol. Life Sci. 2012; 69: 3159-60.
133. Sancho P, Fabregat I. The NADPH oxidase inhibitor VAS2870 impairs cell growth and enhances TGF-β-induced apoptosis of liver tumor cells. Biochem. Pharmacol. 2011; 81: 917-24.
134. Sedeek M, Callera G, Montezano A et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: Implications in type 2 diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2010; 299: F1348-58.
135. Green DE, Murphy TC, Kang BY et al. The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. Am. J. Respir. Cell Mol. Biol. 2012; 47: 718-26.
136. Cayatte AJ, Rupin A, Oliver-Krasinski J et al. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets NADPH oxidase. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 1577-84.
137. Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vascul. Pharmacol. 2012; 56: 216-31.
138. Juhasz A, Ge Y, Markel S et al. Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. Free Radic. Res. 2009; 43: 523-32.
139. Shimada K, Nakamura M, Anai S et al. A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. Cancer Res. 2009; 69: 3157-64.
140. Desouki MM, Kulawiec M, Bansal S, Das G, Singh KK. Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors. Cancer Biol. Ther. 2005; 4: 1367-73.
141. Block K, Gorin Y, New DD et al. The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin. Am. J. Pathol. 2010; 176: 2447-55.
142. Arnold RS, He J, Remo A et al. Nox1 expression determines cellular reactive oxygen and modulates c-fos-induced growth factor, interleukin-8, and Cav-1. Am. J. Pathol. 2007; 171: 2021-32.
143. Block K, Gorin Y. Aiding and abetting roles of NOX oxidases in cellular transformation. Nat. Rev. Cancer 2012; 12: 627-37.
144. Brar SS, Kennedy TP, Sturrock AB et al. An NAD(P)H oxidase regulates growth and transcription in melanoma cells. Am. J. Physiol. Cell Physiol. 2002; 282: C1212-24.
145. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 2008; 68: 1777-85.
146. Kikuchi H, Hikage M, Miyashita H, Fukumoto M. NADPH oxidase subunit, gp91(phox) homologue, preferentially expressed in human colon epithelial cells. Gene 2000; 254: 237-43.
147. Shimada K, Fujii T, Anai S, Fujimoto K, Konishi N. ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder. BMC Urol. 2011; 11: 22.
148. Bauer KM, Hummon AB, Buechler S. Right-side and left-side colon cancer follow different pathways to relapse. Mol. Carcinog. 2012; 51: 411-21.
149. Weyemi U, Caillou B, Talbot M et al. Intracellular expression of reactive oxygen species-generating NADPH oxidase NOX4 in normal and cancer thyroid tissues. Endocr. Relat. Cancer 2010; 17: 27-37.
150. Huang WC, Li X, Liu J, Lin J, Chung LWK. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol. Cancer Res. 2012; 10: 133-42.
151. Kamiguti AS, Serrander L, Lin K et al. Expression and activity of NOX5 in the circulating malignant B cells of hairy cell leukemia. J. Immunol. 2005; 175: 8424-30.
152. Gatley S, Martin J. Some aspects of the pharmacology of diphenyleneiodonium, a bivalent iodine compound. Xenobiotica 1979; 9: 539-46.
153. Holland JA, O'Donnell RW, Chang M-M, Johnson DK, Ziegler LM. Endothelial cell oxidant production. Effect of NADPH oxidase inhibitors. Endothelium 2000; 7: 109-19.
154. Cooper JM, Petty RK, Hayes DJ, Morgan-Hughest JA, Clark JB. Chronic administration of the oral hypoglycaemic agent diphenyleneiodonium to rats: An animal model of impaired oxidative phosphorylation (mitochondrial myopathy). Biochem. Pharmacol. 1988; 37: 687-94.
155. Schäppi MG, Jaquet V, Belli DC, Krause K-H. Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin. Immunopathol. 2008; 30: 255-71.